It also offers the custom development and manufacturing of specialty chemicals and composites to support the electronics, aerospace, food and agrochemical industries.
Swiss pharmaceutical company Lonza has, on Feb 9, signed an agreement with private equity bidders Bain Capital and Cinven to divest its Specialty Ingredients business and operations for an enterprise value of CHF4.2 billion ($6.22 billion).
Lonza’s Specialty Ingredients business is a leading provider of microbial control solutions for professional hygiene and personal care products, which operates across 17 manufacturing sites globally.
